Inovio Stock Leadership


USD 1.98  0.05  2.59%   

Inovio Pharmaceuticals employes about 317 people. The company is managed by 26 executives with total tenure of roughly 164 years, averaging almost 6.0 years of service per executive having 12.19 employees per reported executive. Inspection of Inovio Pharmaceuticals management performance can provide insight into the company performance. Note, employee sentiment is becoming a valuable factor that investors use to determine the amount of risk that may be associated with Inovio Pharmaceuticals future performance.
Please see Risk vs Return Analysis.
  Joseph Kim  CEO
CEO and President Director and Member of Fin. Committee
  Jong Kim  CEO
President CEO, Director
  Jacqueline Shea  CEO
Pres CEO

Inovio Pharmaceuticals Return on Sales


Inovio Pharmaceuticals Management Team Effectiveness

Inovio Pharmaceuticals has Return on Asset of (0.4273) % which means that on every $100 spent on asset, it lost $0.4273. This is way below average. In the same way, it shows return on shareholders equity (ROE) of (0.9227) %, meaning that it generated no profit with money invested by stockholders. Inovio Pharmaceuticals management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return on Investment is estimated to slide to -72.67. The value of Return on Average Assets is estimated to slide to -63.27. Inovio Pharmaceuticals Revenue to Assets are quite stable at the moment as compared to the past year. The company's current value of Revenue to Assets is estimated at 0.003673. Asset Turnover is expected to rise to 0.003517 this year, although the value of Total Assets Per Share will most likely fall to 2.05.
Weighted Average Shares is expected to rise to about 225.3 M this year. Weighted Average Shares Diluted is expected to rise to about 225.3 M this year

Inovio Pharmaceuticals Workforce Comparison

Inovio Pharmaceuticals is rated third overall in number of employees category among related companies. The total workforce of Health Care industry is currently estimated at about 19,696. Inovio Pharmaceuticals claims roughly 317 in number of employees contributing just under 2% to equities under Health Care industry.

Inovio Pharmaceuticals Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Inovio Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Inovio Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Inovio Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Inovio Pharmaceuticals Benchmark Summation

Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Highest value over a specified period line plots max value of Inovio Pharmaceuticals price series.

Inovio Pharmaceuticals Notable Stakeholders

An Inovio Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Inovio Pharmaceuticals often face trade-offs trying to please all of them. Inovio Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Inovio Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Joseph Kim - CEO and President Director and Member of Fin. CommitteeProfile
Jong Kim - President CEO, DirectorProfile
Jacqueline Shea - Pres CEOProfile
Avtar Dhillon - Non-Executive Chairman of the BoardProfile
Niranjan Sardesai - COOProfile
Mort Collins - Independent DirectorProfile
Adel Mahmoud - Independent DirectorProfile
Wendy Yarno - DirectorProfile
Morton Collins - Independent DirectorProfile
Nancy Wysenski - DirectorProfile
Ann Miller - DirectorProfile
George Bickerstaff - DirectorProfile
Lota Zoth - DirectorProfile
Simon Benito - Independent DirectorProfile
Angel Cabrera - Independent DirectorProfile
David Weiner - DirectorProfile
Mark Bagarazzi - Chief Medical OfficerProfile
Asli Gevgilili - Chief OfficerProfile
Ben Matone - Director RelationsProfile
Daniel Jordan - VP OperationsProfile
Peter Kies - Chief OfficerProfile
Jeffrey Skolnik - VP DevelProfile
Robert Juba - VP ManagementProfile
E MBA - VP AssuranceProfile
Laurent Humeau - Chief Scientific OfficerProfile
Robert JD - G CounselProfile

About Inovio Pharmaceuticals Management Performance

The success or failure of an entity such as Inovio Pharmaceuticals often depends on how effective the management is. Inovio Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Inovio management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Inovio management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for 2022
Return on Investment(67.35) (72.67) 
Return on Average Assets(58.64) (63.27) 
Return on Average Equity(70.55) (76.12) 
Return on Invested Capital(0.65) (0.70) 
Return on Sales(170.01) (174.48) 
The data published in Inovio Pharmaceuticals' official financial statements usually reflect Inovio Pharmaceuticals' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Inovio Pharmaceuticals. For example, before you start analyzing numbers published by Inovio accountants, it's critical to develop an understanding of what Inovio Pharmaceuticals' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Inovio Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Inovio Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Inovio Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Inovio Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Inovio Pharmaceuticals' management to manipulate its earnings.

Inovio Pharmaceuticals Workforce Analysis

Traditionally, organizations such as Inovio Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Inovio Pharmaceuticals within its industry.

Inovio Pharmaceuticals Manpower Efficiency

Return on Inovio Pharmaceuticals Manpower

Revenue Per Employee5.7 K
Revenue Per Executive68.3 K
Net Loss Per Employee1 M
Net Loss Per Executive11.7 M
Working Capital Per Employee442.9 K
Working Capital Per Executive5.4 M
Today, most investors in Inovio Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Inovio Pharmaceuticals' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's per employee growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Inovio Pharmaceuticals per employee as a starting point in their analysis.

Per Employee

Inovio Pharmaceuticals Per Employee Growth Over Time

Net Income Per Employee

(1.03 Million)

Inovio Pharmaceuticals Net Income Per Employee is quite stable at the moment as compared to the past year. The company's current value of Net Income Per Employee is estimated at (1.03 Million)

Revenue Per Employee


Inovio Pharmaceuticals Revenue Per Employee is quite stable at the moment as compared to the past year. The company's current value of Revenue Per Employee is estimated at 5,746
Please see Risk vs Return Analysis. You can also try Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.

Complementary Tools for analysis

When running Inovio Pharmaceuticals price analysis, check to measure Inovio Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inovio Pharmaceuticals is operating at the current time. Most of Inovio Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Inovio Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Inovio Pharmaceuticals' price. Additionally, you may evaluate how the addition of Inovio Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Bond Directory
Find actively traded corporate debentures issued by US companies
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Is Inovio Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inovio Pharmaceuticals. If investors know Inovio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inovio Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
494 M
Quarterly Revenue Growth YOY
Return On Assets
Return On Equity
The market value of Inovio Pharmaceuticals is measured differently than its book value, which is the value of Inovio that is recorded on the company's balance sheet. Investors also form their own opinion of Inovio Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Inovio Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inovio Pharmaceuticals' market value can be influenced by many factors that don't directly affect Inovio Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inovio Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Inovio Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inovio Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.